Pfizer and BioNTech Release Early Positive Data from Phase 1 German Trial

Pfizer and BioNTech have released preliminary data from their phase 1/2 COVID-19 vaccine trial in Germany, in which their lead vaccine BNT162b1 induced immune responses in patients.

The trial tested the vaccine in 60 healthy volunteers who either received two doses of the vaccine at 1mg, 10 mcg, 30 mcg and 50 mcg doses, or one single 60 mcg injection. Those who received two doses generated high levels of neutralizing antibodies after their second dose.

The vaccine also generated a strong T-cell response, which helps immune response against the virus.